New targeted drug shows promise for tough ovarian cancer

NCT ID NCT05043922

Ongoing Disease control Sponsor: Haihe Biopharma Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a drug called CYH33 in 93 women with recurrent ovarian, fallopian tube, or peritoneal clear cell carcinoma that has a specific genetic change (PIK3CA mutation). The drug works by blocking a protein that helps cancer grow. The main goal is to see if it shrinks tumors. Participants must have already tried standard chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CYH33 (a PI3Kα inhibitor)
What this could lead to: If successful, this could provide a new targeted treatment option for people with a hard-to-treat form of ovarian cancer that has returned after standard chemotherapy.
What could go wrong: This is an early-phase trial with only 93 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects like high blood sugar or rash.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube clear cell adenocarcinoma ovarian cancer ovarian clear cell cancer Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER RECURRENT CANCER

Contacts and locations

Locations

Beijing Obstetrics and Gynecology Hospital, Capital Medical University

Beijing, China
Chinese PLA General Hospital

Beijing, China
Harbin Medical University Cancer Hospital

Harbin, China
Hokkaido University Hospital

Sapporo, Japan
Hubei Cancer Hospital

Hubei, China
Hunan Cancer Hospital

Hunan, China
Jiangsu Province Hospital

Nanjing, China
Jikei University Hospital

Minato-Ku, Tokyo, Japan
Keio University Hospital

Shinjuku-Ku, Tokyo, Japan
Kurume University Hospital

Kurume, Fukuoka, Japan
Nagoya University Hospital

Nagoya, Japan
National Cancer Center Hospital

Chuo Ku, Tokyo, Japan
Niigata University Medical & Dental Hospital

Niigata, Japan
Obstetrics & Gynecology Hospital of Fudan University

Shanghai, China
Okayama University Hospital

Okayama, Japan
Osaka University Hospital

Suita, Osaka, Japan
Qilu Hospital of Shandong University

Jinan, China
Qingdao Central Hospital

Qingdao, China
Shanghai First Maternity and Infant Hospital

Shanghai, China
Shikoku Cancer Center

Matsuyama, Japan
Sir Run Run Shaw Hospital， School of Medicine, Zhejiang University

Zhejiang, China
Sun Yat-sen University Cancer Center

Guangdong, China
The First Affiliated Hospital of Chongqing Medical University

Chongqing, China
The First Affiliated Hospital of Hainan Medical College

Haikou, China
The First Affiliated Hospital of Xi'an Jiaotong University

Xi'an, China
The First Affiliated Hospital, Sun Yat-sen University

Guangdong, China
The First Affiliated Hospital, Zhejiang University School of Medicine

Hangzhou, China
The People's Hospital Of Guangxi Zhuang Autonomous Region

Nanning, China
The Southwest Hospital of AMU

Chongqing, China
The Third People's Hospital of Hainan Province

Hainan, China
Tianjin Medical University General Hospital

Tianjin, China
Tohoku University Hospital

Sendai, Japan
West China Second University Hospital, Sichuan University

Sichuan, China
Xiaohua wu

Shanghai, China
Zhejiang Cancer Hospital

Hangzhou, China
Zhongnan Hospital of Wuhan University

Wuhan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.